Affordable Access

Publisher Website

Amyotrophic lateral sclerosis: lessons in trial design from recent trials

Authors
Journal
Journal of the Neurological Sciences
0022-510X
Publisher
Elsevier
Publication Date
Volume
152
Identifiers
DOI: 10.1016/s0022-510x(97)00240-2
Keywords
  • Amyotrophic Lateral Sclerosis
  • Trial Design
  • Comparability
  • Disease Progression
  • Quality Of Life
Disciplines
  • Design
  • Medicine

Abstract

Abstract The recent history of clinical trials in ALS is marked by a great diversity in trial design. This has limited the comparability of the trial results, and has resulted in intense discussions about which parameters should or should not be evaluated when testing a new drug for ALS. This article discusses, without any claim to completeness, some aspects of trial design in relation to past, ongoing and future ALS trials, including: choice of endpoints, measurement of disease progression, assessment of quality of life, placebo-controlled trials, open-label trials, collaboration with the industry, and methods for investigating mechanisms of action of experimental drugs.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Amyotrophic lateral sclerosis: lessons in trial de...

on Journal of the Neurological Sc... October 1997

Designing Clinical Trials in Amyotrophic Lateral S...

on Physical Medicine and Rehabili... Jan 01, 2008

Enhancing clinical trials in neurodegenerative dis...

on Current Opinion in Neurology December 2012
More articles like this..